Spruce Biosciences, Inc. SPRB
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -56.38%
- 1 year
- -62.97%
5D -6.17 (-13.70%)
- Market cap
- 109.21M
- Revenue (ttm)
- 7.10M
- EPS (ttm)
- -33.29
- Shares out
- 41.30M
- Forward P/E
- -0.41
- YTD return
- -56.38%
- 1-year return
- -62.97%
- 50-day average
- 0.50446
- Volume
- 108.29K
- Avg volume
- 88.62K
- Open
- 39.97
- Previous close
- 40.49
- Day's range
- 38.00 – 40.96
- 52-week range
- 38.00 – 112.26
- Analysts
- Hold
- Price target
- 1.83 (-95.2%)
Key statistics
- 200-day average
- 0.668845
- Enterprise value
- -40.58M
- Price / sales
- 2.20
- Price / book
- 0.30
- Revenue growth
- -80.40%
- Free cash flow
- -35.07M
- Total cash
- 60.05M
- Total debt
- 2.96M
- Return on equity
- -57.55%
- Short % of float
- 0.08%
Fundamental scorecard
4 of 25 checks passed on SPRB’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.27 | -0.21 | +0.06 | +22.22% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.22 | +0.11 | +33.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.32 | -0.28 | +0.04 | +12.50% |
| May 13, 2024 | Mar 1, 2024 | -0.32 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | reit | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sprucebiosciences.com
News
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY
Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Plans Spin-Off To Stockholders
Your note
Sign in to keep a note on SPRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARLTON RALPH WILLIAM III | Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 161,339 |
| GHARIB SAMIR M | President | Conversion of Exercise of derivative security | Dec 15, 2024 | 350,550 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 20, 2024 | 2,550,000 |
| O DONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| ODONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| SZWARCBERG JAVIER B M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 467,191 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rivervest Venture Management LLC | 7.11% | 2,936,281 | 1.11M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.01% | 2,896,518 | 1.09M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.32% | 2,609,125 | 984.94K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.05% | 1,259,151 | 475.33K | Sep 29, 2024 |
| Vanguard Group Inc | 2.04% | 843,844 | 318.55K | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 1.91% | 787,007 | 297.10K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 638,558 | 241.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 197,187 | 74.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 153,228 | 57.84K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 40,000 | 15.10K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 36,510 | 13.78K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 31,503 | 11.89K | Oct 30, 2024 |
